Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Ventyx Biosciences Inc shares valued at $2,019 were sold by Nuss John on Apr 02 ’25. At $1.07 per share, Nuss John sold 1,887 shares. The insider’s holdings dropped to 467,226 shares worth approximately $0.71 million following the completion of this transaction.
Also, Nuss John sold 21,119 shares, netting a total of over 49,841 in proceeds. Following the sale of shares at $2.36 each, the insider now holds 464,582 shares.
Before that, Nuss John had added 21,119 shares to its account. In a trade valued at $49,842, the Officer bought Ventyx Biosciences Inc shares for $2.36 each.
As published in a research note from Wells Fargo on March 12, 2024, Ventyx Biosciences Inc [VTYX] has been rated up from an Equal weight to an Overweight and the price target has been revised to $16 from $7. Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid March. As of November 07, 2023, Wells Fargo has decreased its “an Overweight” rating to a “an Equal weight” for VTYX. Earlier on November 07, 2023, Stifel downgraded its rating. Their new recommendation was “a Hold” for VTYX stock which previously was a “a Buy”.
Analyzing VTYX Stock Performance
During the last five days, there has been a surge of approximately 29.66%. Over the course of the year, Ventyx Biosciences Inc shares have dropped approximately -30.14%. A 50-day SMA is recorded $1.2227, while a 200-day SMA reached $1.8853.
Support And Resistance Levels for Ventyx Biosciences Inc (VTYX)
RSI (Relative Strength Index) is 64.27 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.2069, which suggests the price will decrease in the coming days. Percent R is at 15.79%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
